麦美华—快速诊断技术与试剂的研发和生产销售商今日宣布：通过与泰普生物的战略合作以实现在中国的快速发展。泰普生物是中国诊断（试剂）领域的主要的企业之一。
去年有着近3000万美金销售成绩的泰普已经建立了良好的医疗客户基础，拥有了29个省市的2000多家医院和医疗诊断机构。泰普的产品涵盖了45种分子诊断产品，包括（在这个领域的）一些高端品牌。泰普同样拥有许多的专家、学者，博士，通过中国的病理学委员会工作于整个中国的的研究院和医院中。
“这种战略合作能带来强大的销售和泰普已经建立好的强大的市场平台，通过与麦美华世界水准的产品合作，提供给客户高质量的诊断方式，对合作双方来说互利互惠的。”麦美华董事长陈锦华说，“对我们而言，中国是一个长期的需要主动开拓的市场，和泰普的合作是我们开拓中国市场的必然选择。”
麦美华与泰普最初的合作方式是通过泰普的销售渠道来增加我们在中国的产品销售。在上个月，泰普将麦美华的快速检测试剂进行了预售前的客户测试，取得了良好的反馈。除此之外，泰普还将它们送往中国医疗疾病诊断与预防（CDC）中心进行检测。
陈董事长说：“我们相信通过与泰普的战略合作，将来会发展为共同研发快速诊断试剂，技术转让，以及共同合作研发新项目上来。如今的中国市场不断变化，新的医疗体系将会形成，麦美华和泰普将共同致力于技术优化和产品成本优化。”
2009年4月，中国政府在国家医疗体系改革上投入了1250亿美元，主要用于建立基础医疗设施，普及城市和农村的公共医疗服务，为全体居民提供基础医疗和药物计划，以及进行公共医疗体系的重建。
“我们很高兴能和麦美华合作，共同开发中国市场，同时（可以）为我们的顾客提供最新的诊断方式。如今的诊断领域不断变化，泰普与麦美华合作可以及时响应市场需求”泰普董事长姚铭锋说，“我们与麦美华的长期战略合作将灵活地根据市场需求研发及将研发成果商业化。”
除了医疗产品的销售和物流配送外，泰普还计划建立自己独立的医疗诊断中心，用来为客户提供方便快捷的诊断服务。泰普已经考察了许多的城市和地区来建立临检中心，直接提供自己的医疗产品和医学专家服务。
原文:
MedMira Enters Strategic Partnership with Triplex International Biosciences to Accelerate Growth in China
Halifax, Nova Scotia June 30, 2009 - MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that it is making progress on market development in China through the creation of a strategic partnership with Triplex International Biosciences Co., Ltd. (Triplex), a major player in China’s diagnostics sector.
With recorded sales revenue of nearly USD $30 million last year, Triplex has a well established healthcare customer base, which includes over 2,000 hospitals and medical institutions across 29 provinces and autonomous regions within China. The Triplex product line is comprised of over 45 molecular pathology diagnostics products, including some of the top brands in the industry. Triplex also has access to many experts, academics and doctors working in hospitals and research institutions across China through the Chinese Committee of Pathology.
“This partnership brings the strong sales and marketing platform that Triplex has built in China together with MedMira’s world-class products, to offer customers quality diagnostic solutions and increase revenue potential for both companies,” said Hermes Chan, CEO of MedMira Inc. “For us China is a long-term business initiative and working with Triplex is a natural extension of MedMira’s growth strategy for the China market.”
MedMira will initially be working with Triplex to increase product sales in China through their existing distribution channels. Over the course of the last few months, Triplex has undertaken market testing with MedMira rapid tests and the feedback has been very positive. In addition to these pre-sales customer trials, Triplex also engaged the China Centers for Disease Control and Prevention (CDC) to evaluate the MedMira tests.
Chan continued, ”We believe our partnership with Triplex will evolve to include co-development of new rapid tests, technology transfers, and collaborative research projects in the future. Market conditions are changing rapidly in the China as new healthcare system reforms take shape. Together MedMira and Triplex can capitalize on the need for improved and cost-effective diagnostics.”
In April 2009, China’s government announced a $125 billion USD investment in significant reforms to their country’s healthcare system. Major initiatives include the establishment of basic medical services for all urban and rural residents, universal access to public health services, a basic medical and drug plan for all residents, and the reorganization of the public hospital system.
“We are pleased to work with MedMira in expanding their access to the China market and offer our customers new rapid diagnostic solutions. The diagnostics sector and overall healthcare market here in China is rapidly changing and together Triplex and MedMira can respond to market demand for better, faster diagnostics,” said Yiu Ming Fung, President and Chairman of Triplex. “Our long-term growth strategies are in line with MedMira’s and our partnership enables the flexibility to develop and commercialize new rapid tests to meet market demand.”
In addition to sales and distribution of diagnostic products, Triplex intends to operate independent diagnostic centres to provide fast and convenient medical testing services. Triplex has identified a number of cities and regions to set up its diagnostic centers where they will serve the community directly using Triplex’s wide range of diagnostic products and technical expertise.
About Triplex International Biosciences Co., Ltd.
Triplex is one of the leading molecular pathology diagnostic companies in China and its line of diagnostic solutions is one of the tope brands in the industry. Over the past five years, Triplex has grown from seven people to a team of 170 supporting the Company’s annual sales growth rate of 400 percent. Triplex sells more than 45 products to over 2000 hospitals and medical institutions across 29 provinces and cities in China. The Company has also developed more than 30 diagnostic products through its Engineering Laboratory for Molecular Diagnostic Technology in Fuzhou, three R&D centers, and five joint R&D bases with Peking University Medical School, the Fourth Military Medical University in Xi-an, Sichuan University, Fujian Medical University, as well as CAS Shanghai Life Sciences Research Institute. To learn more about Triplex visit www.tibchina.com.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal®, MiraWell®, MiraCare™ and Multiplo™ brands in global markets. MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
